RR
Robin Shane Readnour

Robin Shane Readnour insider trades: AN2 Therapeutics (ANTX) stock buys and sales

AN2 Therapeutics Last trade Sep 9, 2026 16 Form 4 filings
$317K
Sold, last 12 months
3 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2022
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Robin reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Sep 9, 2026ANTX↓ Sell$7K
Sep 8, 2026ANTX↓ Sell$97K
Aug 17, 2026ANTX↓ Sell$213K
Dec 10, 2024ANTX↑ Buy$87K
Nov 27, 2024ANTX↑ Buy$106K
Nov 20, 2024ANTX↑ Buy$213K
Jan 12, 2024ANTX↓ Sell$31K
Jan 10, 2024ANTX↓ Sell$80K
Mar 29, 2022ANTX↑ Buy$2.3M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ANTX insiders

Open-market trades in the last 12 months

About Robin Shane Readnour's insider trades

Robin Shane Readnour is an insider at AN2 Therapeutics (ANTX). Since Mar 29, 2022, Robin has reported 4 open-market purchases worth $2.7M and 5 sales worth $428K on SEC Form 4. In the last 12 months: 3 sales ($317K).

Their filings also include grants and awards (7 filings), shares returned to the company (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ANTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.